|
|
|
|
Direct Cost |
Indirect Cost |
|
1DP1DA039543-01 |
TOWARDS A MORE RELEVANT MODEL OF HIV INFECTION |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIDA |
$500,000 |
$380,000 |
$880,000 |
1F30CA200247-01 |
Mitochondrial Mutagenesis and Dysfunction in Cancer Metabolism |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$37,319 |
|
$37,319 |
1K01CA188151-01A1 |
Targeted Alpha Radioimmunotherapy with Haploidentical Bone Marrow Transplantation for AML |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$156,500 |
$12,520 |
$169,020 |
1K01ES026842-01 |
Connecting Single Cell Heterogeneity to Clinical Descriptors of Clonal Evolution in Acute Myeloid Leukemia |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIEHS |
$111,088 |
$8,527 |
$119,615 |
1K23AI119133-01 |
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell Transplantation |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$163,850 |
$12,547 |
$176,397 |
1K99CA190836-01A1 |
Cell Biological Mechanisms of Melanoma Cell Motility in vivo |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$105,900 |
$8,472 |
$114,372 |
1K99GM112941-01A1 |
Causes and human health consequences of the evolution of retroelements and host restriction factors |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIGMS |
$83,333 |
$6,667 |
$90,000 |
1K99GM114436-01 |
Mechanisms of meiotic drive and the functional consequences of rapid genome evolution in Schizosaccharomyces |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIGMS |
$83,333 |
$6,667 |
$90,000 |
1P01HL122173-01A1 |
Cell and Gene Therapy for Nonmalignant Blood Disorders |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NHLBI |
$1,678,686 |
$992,229 |
$2,670,915 |
1R01AG048209-01A1 |
MsFLASH: Living a Healthy Menopause |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIA |
$977,530 |
$422,470 |
$1,400,000 |
1R01AI121259-01 |
Statistical Methods for Adherence Issues in HIV Prevention Research |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NIAID |
$435,889 |
$194,283 |
$630,172 |
1R01CA177736-01A1 |
FFPE Validation of a Survival Gene Signature in HPV-Negative Oral Cavity Cancer |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$412,709 |
$310,891 |
$723,600 |
1R01CA181449-01A1 |
Interrogation of MLL2 as a tumor suppressor gene in lung cancer |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$228,750 |
$173,850 |
$402,600 |
1R01CA184075-01A1 |
PALS: Prostate Cancer Active Lifestyle Study |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$348,675 |
$193,521 |
$542,196 |
1R01CA188341-01A1 |
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$243,829 |
$171,628 |
$415,457 |
1R01CA189184-01A1 |
Discovery and verification of novel biomarkers of colorectal cancer recurrence |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$744,585 |
$339,553 |
$1,084,138 |
1R01CA189532-01A1 |
Methods for Integrating Functional Data into Complex Disease Genetic Analyses |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$278,072 |
$202,182 |
$480,254 |
1R01CA190957-01A1 |
MYC-dependent loss of splicing fidelity in Glioblastoma multiforme |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$270,688 |
$193,616 |
$464,304 |
1R01CA192267-01 |
Monitoring disease progression in follicular lymphoma with next-gen sequencing |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$306,363 |
$207,490 |
$513,853 |
1R01CA192402-01A1 |
Estimating Overdiagnosis in Cancer Screening Studies |
FRED HUTCHINSON CANCER RESEARCH CENTER |
NCI |
$318,305 |
$199,941 |
$518,246 |